NATCAPSUQ Natural Capsules Q4 FY25 results (Jan–Mar 2025) and concall
Natural Capsules reported a mixed Q4 and FY25, with revenue growth but significant PAT decline for the full year. The company is optimistic about future growth driven by the HPMC capsule business, benefiting from new US anti-dumping duties on Chinese imports, and the API segment, despite initial challenges and pricing pressures. Regulatory delays impacted the API project, but management expects a ramp-up in sales and profitability from Q1 FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 41 | 43 | 44 |
| EBITDA | 5 | 5 | 5 |
| Net profit | 1 | 2 | 3 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
